MétaCan
Menu
← Back to cohort
Record W7117117763 · doi:10.1002/alz70856_097403

Neuroligin fragments as blood‐based biomarkers for early detection of Alzheimer's disease

2025· article· en· W7117117763 on OpenAlexaff
Milton Guilherme Forestieri Fernandes, Maxime Pinard, Esen Sokullu, Jean‐François Gagnon, Frédéric Calon, Benoit Coulombe, Jonathan Brouillette

Bibliographic record

VenueAlzheimer s & Dementia · 2025
Typearticle
Languageen
FieldMedicine
TopicAlzheimer's disease research and treatments
Canadian institutionsCentre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-MontréalUniversité de MontréalUniversité LavalUniversité du Québec à MontréalHôpital du Sacré-Cœur de MontréalMontreal Clinical Research Institute
Fundersnot available
KeywordsDiseaseNeuroliginBiomarkerBlood testFibulin

Abstract

fetched live from OpenAlex

BACKGROUND: Alzheimer's disease (AD) progresses slowly, with advanced neurodegeneration already present by the time clinical symptoms appear. To enhance the effectiveness of potential treatments, biomarkers that can detect the disease in its early stage are needed. Neuroligin (NLGN) is present in synapses, which are affected early in AD. Fragments of NLGN can be detected in the blood during the initial stages of the disease, suggesting their potential as biomarkers for early detection. In this study, we evaluated the potential of NLGN fragments as blood-based biomarkers for the early stages of Alzheimer's disease. METHOD: Blood samples were obtained from the CIMA-Q cohort, which includes individuals at preclinical and prodromal stages of AD, those in the early stages of the disease, and cognitively healthy individuals. To quantify the levels of NLGN fragments in blood, we employed multiplexing combined with high-resolution tandem mass spectrometry. Statistical analyses were then conducted to examine differences in NLGN fragment levels across diagnostic groups and to assess their correlation with established indicators of AD progression, including plasma phosphorylated Tau (pTau) levels, hippocampal volume, and Mini-Mental State Examination (MMSE) score. RESULT: The levels of certain NLGN fragments were elevated in individuals with amnestic mild cognitive impairment (aMCI), a prodromal stage of AD, and in the early stages of AD. A significant positive correlation was observed between plasma phosphorylated Tau (pTau) levels and specific NLGN fragments. Additionally, in non-healthy individuals (aMCI and early AD), NLGN fragment levels showed an inverse correlation with MMSE scores and hippocampal volume. CONCLUSION: Identifying changes in synaptic proteins in the blood of individuals with aMCI and early AD could be instrumental for earlier disease detection. Our findings reveal that blood levels of specific NLGN fragments are elevated in the prodromal and early stages of AD and correlate with key indicators of disease onset, particularly plasma levels of pTau. These results suggest that NLGN fragments could serve as a primary care screening test and be incorporated into a panel of early biomarkers of AD.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.006

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.022
GPT teacher head0.311
Teacher spread0.289 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueAlzheimer s & Dementia→Same topicAlzheimer's disease research and treatments→French-language works237,207→